AZD 5069

Drug Profile

AZD 5069

Alternative Names: AZD5069

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; MedImmune
  • Class Antiasthmatics; Small molecules
  • Mechanism of Action Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Coronary disorders; Head and neck cancer; Solid tumours
  • Phase I/II Pancreatic cancer
  • Discontinued Asthma; Bronchiectasis; Chronic obstructive pulmonary disease

Most Recent Events

  • 13 Jun 2017 Institute of Cancer Research, Astellas Pharma and AstraZeneca plan a phase I/II trial for Prostate cancer (Combination therapy, Metastatic disease) (NCT03177187)
  • 16 Dec 2016 Phase-II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium, Germany, Italy, Spain, United Kingdom, USA (unspecified route)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top